vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $143.3M, roughly 1.3× Piedmont Realty Trust, Inc.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -31.4%, a 32.3% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 0.4%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 0.0%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
FOLD vs PDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $143.3M |
| Net Profit | $1.7M | $-45.0M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | — |
| Net Margin | 0.9% | -31.4% |
| Revenue YoY | 23.7% | 0.4% |
| Net Profit YoY | -88.5% | -27.9% |
| EPS (diluted) | $0.00 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | $185.2M | $142.9M | ||
| Q3 25 | $169.1M | $139.2M | ||
| Q2 25 | $154.7M | $140.3M | ||
| Q1 25 | $125.2M | $142.7M | ||
| Q4 24 | $149.7M | $143.2M | ||
| Q3 24 | $141.5M | $139.3M | ||
| Q2 24 | $126.7M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $1.7M | $-43.2M | ||
| Q3 25 | $17.3M | $-13.5M | ||
| Q2 25 | $-24.4M | $-16.8M | ||
| Q1 25 | $-21.7M | $-10.1M | ||
| Q4 24 | $14.7M | $-30.0M | ||
| Q3 24 | $-6.7M | $-11.5M | ||
| Q2 24 | $-15.7M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.3% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | -6.3% | — | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 11.8% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | 0.9% | -30.3% | ||
| Q3 25 | 10.2% | -9.7% | ||
| Q2 25 | -15.8% | -12.0% | ||
| Q1 25 | -17.3% | -7.1% | ||
| Q4 24 | 9.8% | -20.9% | ||
| Q3 24 | -4.8% | -8.3% | ||
| Q2 24 | -12.4% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $0.00 | $-0.34 | ||
| Q3 25 | $0.06 | $-0.11 | ||
| Q2 25 | $-0.08 | $-0.14 | ||
| Q1 25 | $-0.07 | $-0.08 | ||
| Q4 24 | $0.05 | $-0.25 | ||
| Q3 24 | $-0.02 | $-0.09 | ||
| Q2 24 | $-0.05 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $2.3M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $1.5B |
| Total Assets | $949.9M | $4.0B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | $293.5M | $731.0K | ||
| Q3 25 | $263.8M | $3.0M | ||
| Q2 25 | $231.0M | $3.3M | ||
| Q1 25 | $250.6M | $2.9M | ||
| Q4 24 | $249.9M | $109.6M | ||
| Q3 24 | $249.8M | $133.6M | ||
| Q2 24 | $260.1M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $2.2B | ||
| Q3 25 | $392.0M | $2.2B | ||
| Q2 25 | $391.3M | $2.2B | ||
| Q1 25 | $390.7M | $2.2B | ||
| Q4 24 | $390.1M | $2.2B | ||
| Q3 24 | $389.5M | $2.2B | ||
| Q2 24 | $388.9M | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $274.2M | $1.5B | ||
| Q3 25 | $230.4M | $1.5B | ||
| Q2 25 | $204.3M | $1.5B | ||
| Q1 25 | $193.6M | $1.6B | ||
| Q4 24 | $194.0M | $1.6B | ||
| Q3 24 | $178.8M | $1.6B | ||
| Q2 24 | $132.5M | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $949.9M | $4.0B | ||
| Q3 25 | $868.8M | $4.0B | ||
| Q2 25 | $815.3M | $4.0B | ||
| Q1 25 | $789.8M | $4.0B | ||
| Q4 24 | $785.0M | $4.1B | ||
| Q3 24 | $786.6M | $4.1B | ||
| Q2 24 | $749.5M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 1.49× | ||
| Q3 25 | 1.70× | 1.43× | ||
| Q2 25 | 1.92× | 1.41× | ||
| Q1 25 | 2.02× | 1.40× | ||
| Q4 24 | 2.01× | 1.40× | ||
| Q3 24 | 2.18× | 1.36× | ||
| Q2 24 | 2.93× | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | 110.3% |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.3M | $140.6M | ||
| Q3 25 | $35.7M | $35.8M | ||
| Q2 25 | $-26.5M | $50.1M | ||
| Q1 25 | $7.8M | $3.7M | ||
| Q4 24 | $-3.9M | $198.1M | ||
| Q3 24 | $-23.0M | $42.9M | ||
| Q2 24 | $22.7M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | — | ||
| Q3 25 | $35.3M | — | ||
| Q2 25 | $-28.9M | — | ||
| Q1 25 | $7.5M | — | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-23.3M | — | ||
| Q2 24 | $21.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.9% | — | ||
| Q2 25 | -18.7% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | -16.5% | — | ||
| Q2 24 | 17.0% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PDM
Segment breakdown not available.
